Information Provided By: 
Fly News Breaks for January 8, 2016
JAZZ
Jan 8, 2016 | 08:20 EDT
Leerink analyst Jason Gerberry cut his price target for Jazz Pharmaceuticals to $166 citing a more conservative pricing outlook for Xyrem. In 2015, Jazz decided not take its typical second half of the year price increase on Xyrem, raising the list price only 9% year-over-year, Gerberry tells investors in a research note. Annual price increases over the last three years before 2015 were 38%, 30% and 20%, respectively, the analyst points out. He keeps an Outperform rating on Jazz.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
